Bio-Works Technologies AB (publ) (BIOWKS.ST)
Bio-Works Technologies AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Uppsala, SE. The stock last traded at $3.15, down 0.63% on the session, giving a market capitalisation of $260.8M. Its beta of 0.63 implies it has historically moved less than the broad market.
Bio-Works Technologies AB (publ) is a biotechnology company that specializes in the research, development, production, and distribution of agarose-based separation products. These sophisticated solutions are designed to facilitate the purification of proteins, peptides, and other biomolecules, with a primary focus on the Swedish market. Their comprehensive product portfolio encompasses items such as activated and affinity resins, BabyBio columns, immobilized metal-ion affinity chromatography (IMAC) resins, ion exchange resins, OptioBio glass columns, screening kits, and size exclusion chromatography (SEC) resins. These offerings find use across various applications, including those concerning antibodies, His-tagged proteins, other proteins, peptides, oligonucleotides, and in the purification of viruses and vaccine development. Established in 2006, the company is headquartered in Uppsala, Sweden.
Bio-Works Technologies AB (publ) is most often compared with the following Healthcare names: